Replies to post #197461 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The problem is you are electing to define "end" the way you want to, and ignore all reasonable context.

Nothing says a trial ends with last treatment or even last patient visit, that is your creation.

OTOH, we know a trial is complete when it reaches the defined endpoint (either primary or primary plus all secondaries).

They clearly placed the estimated primary and secondary completion dates in the legally mandated Federal register (clinical trials gov) well before 36 months. There was no ambiguity in those at all. And before you ask, those date are defined as the final primary and secondary, not on a hope for an early IA.

You have seen the protocol that clearly states the endpoints are event driven. Anybody who has followed any clinical trials at knows what that means.

[HappyLibrarian]

Replace “subtle” with ”deceptive” and you have it right.

Flipper is focusing on what the company said in clear terms, publicly and with the inteobvious intent of improving shareholder positive perception of where NWBO and when things would start happening.

This was part of the stringing along of shareholders.